Literature DB >> 15257411

Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease.

Fuat Erdem1, Mehmet Gündoğdu, Ilhami Kiki, Refik Ali Sari, Ahmet Kiziltunç.   

Abstract

Behçet's disease (BD) is a systemic vasculitis of unknown aetiology. Its pathogenesis is related to endothelial cell dysfunction, humoral immune defects, and immune system dysregulation. The aim of this study was to investigate the possible role of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD. We also investigated whether disease activity, age, or duration of BD correlates with VEGF and bFGF. We studied 33 patients and 20 healthy controls. Vascular endothelial growth factor and bFGF serum levels were measured by enzyme-linked immunosorbent assay. We measured acute phase reactants, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). The mean serum VEGF level was significantly higher in patients with BD (398.8+/-222.2 pg/ml) than the control group (193.0+/-122.4 pg/ml) (P=0.002). The levels were similar in both active and inactive BD (P=0.675) but did not correlate with disease duration, CRP, ESR, or age (P>0.05 for each). The bFGF was below detection limits in 18 of 33 patients with BD and ten of 20 controls, and its mean serum level was higher in BD patients (42.4+/-76.9 pg/ml) than controls (29.0+/-9.1 pg/ml), but this difference was not statistically significant (P=0.232). The bFGF levels were similar in both active and inactive BD (P=0.09) and, in patients, correlated with disease duration and CRP (r=0.58, P=0.02; r=-0.57, P=0.02, respectively) but not with ESR or age (P>0.05 for each). Vascular endothelial growth factor may be more important in the pathogenesis of BD than bFGF. Neither growth factor is an activity criterion or inflammatory marker in BD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257411     DOI: 10.1007/s00296-004-0484-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

Review 1.  Behçet's disease and thrombophilia.

Authors:  M Leiba; Y Sidi; H Gur; A Leiba; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Levels of circulating intercellular adhesion molecule-1 in patients with Behçet's disease.

Authors:  Kenan Saglam; M Ilker Yilmaz; Ayse Saglam; Mete Ulgey; Fatih Bulucu; Yavuz Baykal
Journal:  Rheumatol Int       Date:  2002-01       Impact factor: 2.631

Review 3.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.

Authors:  E Robak; A Woźniacka; A Sysa-Jedrzejowska; H Stepień; T Robak
Journal:  Eur Cytokine Netw       Date:  2001 Jul-Sep       Impact factor: 2.737

6.  Increased plasma adrenomedullin levels in patients with Behçet's disease.

Authors:  C Evereklioglu; M Yurekli; H Er; E Ozbek; E Hazneci; M Cekmen; H S Inaloz
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

7.  Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells.

Authors:  C C Zouboulis; J Katsantonis; R Ketteler; R Treudler; E Kaklamani; S Hornemann; P Kaklamanis; C E Orfanos
Journal:  Arch Dermatol Res       Date:  2000-06       Impact factor: 3.017

8.  Systemic endothelial cell markers in primary antiphospholipid syndrome.

Authors:  F M Williams; K Parmar; G R Hughes; B J Hunt
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

9.  Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.

Authors:  E Robak; A Woźniacka; A Sysa-Jedrzejowska; H Stepień; T Robak
Journal:  Lupus       Date:  2002       Impact factor: 2.911

10.  Serum and plasma levels of FGF-2 and VEGF in healthy blood donors.

Authors:  A Larsson; E Sköldenberg; H Ericson
Journal:  Angiogenesis       Date:  2002       Impact factor: 9.596

View more
  12 in total

1.  Aqueous humor IL-8, IL-10, and VEGF levels in Fuchs' uveitis syndrome and Behçet's uveitis.

Authors:  Mert Simsek; Pinar Cakar Ozdal; Filiz Akbiyik; Mehmet Citirik; Nilufer Berker; Yasemin Ozdamar Erol; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2019-05-07       Impact factor: 2.031

2.  Association of Rho-kinase 1 (ROCK1) gene polymorphisms with Behçet's disease.

Authors:  Elif Oguz; Abdullah Tuncay Demiryürek; Yavuz Pehlivan; Bünyamin Kisacik; Esma Ozkara; Serdar Oztuzcu; Belgin Alasehirli; Ahmet Mesut Onat
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

3.  Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.

Authors:  Ishna Auluck; Ayesha Karimi; Simon Taylor
Journal:  Clin Med (Lond)       Date:  2019-11       Impact factor: 2.659

4.  Vascular endothelial growth factor and carotid intima-media thickness in patients with Behçet's disease.

Authors:  Mehmet Akif Oztürk; Selman Unverdi; Suna O Oktar; Neslihan Bukan; Ozlem Gülbahar; Kemal Ureten; Berna Göker; Seminur Haznedaroglu; Gülten Sungur; Tansu Ulukavak Ciftçi; A Mesut Onat
Journal:  Clin Rheumatol       Date:  2008-01-18       Impact factor: 2.980

5.  Behçet's Disease as a Model of Venous Thrombosis.

Authors:  Micaela La Regina; Armen Yuri Gasparyan; Francesco Orlandini; Domenico Prisco
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

6.  The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Yeşim Gedik-Oğuz; F Nilüfer Yalçındağ
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-04       Impact factor: 3.117

7.  Serum prolidase enzyme activity and oxidative status in patients with Behçet's disease.

Authors:  Mehtap Bozkurt; Hatice Yüksel; Serda Em; Pelin Oktayoglu; Mehmet Yildiz; Dicle Akdeniz; Kemal Nas
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

8.  Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection.

Authors:  Fariba Ghassemi; Sohrab Afshari Mirak; Hormoz Chams; Siamak Sabour; Mehdi Nilli Ahmadabadi; Fereidoun Davatchi; Farhad Shahram
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

9.  The Evaluation of the Relationship between sTREM-1, VEGF-B, and VEGF Gene Expression Levels with Disease Activity of Behçet's Patients.

Authors:  Kadir Harmanci; Ozden Yildirim Akan; Timur Pirildar; Pinar Ortan; Cevval Ulman
Journal:  Dis Markers       Date:  2018-10-21       Impact factor: 3.434

Review 10.  Vascular endothelial growth factor (VEGF) in autoimmune diseases.

Authors:  Jozélio Freire Carvalho; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2007-03-06       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.